Lansoprazole-Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 791-794

  Takahashi, Kazushige ^a,b   Motohashi, Hideyuki ^a   Yonezawa, Atsushi ^a   Okuda, Masahiro ^a   Ito, Noriyuki ^b   Yamamoto, Shingo ^b   Ogawa, Osamu ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CYP2C19; Kidney transplantation; Lansoprazole; Tacrolimus

Indexed keywords

CYTOCHROME P450 2C19; FAMOTIDINE; LANSOPRAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION TEST; LIVING DONOR; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; TREATMENT WITHDRAWAL; ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG SYNERGISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMORPHISM, GENETIC; TACROLIMUS;

EID: 1942438697     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D366     Document Type: Article

References (18)

1. Shapiro R, Jordan ML, Scantlebury VP. A prospective randomized trial of tacrolimus-based immunosuppression after renal transplantation. Transplantation 1995;59:485-90.
2. Christianss U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;41:813-51.
3. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996;31:9-28.
4. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(suppl 3):27-36.
5. Grenier FC, Luczkiw J, Bergmann M, Lunetta S, Morrison M, Blonski D, et al. A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 1991;23:2748-9.
6. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997;62:287-92.
7. Package insert. Tacrolimus II reagent pack for IMx amalyzer. Tokyo, Japan: Abbott, Japan, February 2003.
8. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995;29:404-30.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6.
11. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41:913-58.
12. Katsuki H, Nakamura C, Arimori K, Fujiyama S, Nakano M. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 1997;52:391-6.
13. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001;18:721-7.
14. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y. Effect of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 2002;73:303-4.
15. Itagaki F, Homma M, Yuzawa K, Fukao K, Kohda Y. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant Proc 2002;34:2777-8.
16. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003; 43:149-73.
17. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364:551-7.
18. Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. Eur J Clin Pharmacol 2000;56:439-40.